Nagata et al., 2015 - Google Patents
Pharmacokinetic–Pharmacodynamic Analysis of Sunitinib-Induced Thrombocytopenia in Japanese Patients with Renal Cell CarcinomaNagata et al., 2015
View HTML- Document ID
- 6273449788253755369
- Author
- Nagata M
- Ishiwata Y
- Takahashi Y
- Takahashi H
- Saito K
- Fujii Y
- Kihara K
- Yasuhara M
- Publication year
- Publication venue
- Biological and Pharmaceutical Bulletin
External Links
Snippet
The aim of the present study was to clarify the therapeutic range and adequate dose of sunitinib in Japanese renal cell carcinoma patients by means of a pharmacokinetic– pharmacodynamic analysis of sunitinib-induced thrombocytopenia. Six patients with renal …
- 206010043554 Thrombocytopenia 0 title abstract description 55
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagata et al. | Pharmacokinetic–Pharmacodynamic Analysis of Sunitinib-Induced Thrombocytopenia in Japanese Patients with Renal Cell Carcinoma | |
| Garcia-Carbonero et al. | ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy-chemotherapy | |
| Eisen et al. | Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study | |
| Sahu et al. | Targeted therapy in biliary tract cancers—current limitations and potentials in the future | |
| Ullmann | Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole | |
| Hartford et al. | A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies | |
| Wind et al. | Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir | |
| Wang et al. | PARP inhibitors in gastric cancer: beacon of hope | |
| Yi et al. | Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers | |
| Blay | Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib | |
| Walko et al. | Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective | |
| Aung et al. | A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours | |
| Badawi et al. | CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128 | |
| Roux et al. | BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma | |
| Shelepova et al. | Effect of a triphasic oral contraceptive on drug‐metabolizing enzyme activity as measured by the validated Cooperstown 5+ 1 cocktail | |
| Kim et al. | Profile of selumetinib and its potential in the treatment of melanoma | |
| Jeon et al. | Assessment of the drug–drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers | |
| Kosoglou et al. | The effect of multiple doses of ketoconazole or rifampin on the single‐and multiple‐dose pharmacokinetics of vorapaxar | |
| EP3965758A1 (en) | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients | |
| Shen et al. | Effects of voriconazole on the pharmacokinetics of vonoprazan in rats | |
| Son et al. | Pharmacokinetic interaction between rosuvastatin, telmisartan, and amlodipine in healthy male Korean subjects: a randomized, open-label, multiple-dose, 2-period crossover study | |
| Burger | Highlights in experimental therapeutics | |
| De Bruijn et al. | Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism | |
| Toto | Aldosterone blockade in chronic kidney disease: can it improve outcome? | |
| Momper et al. | Pharmacokinetics of low‐dose cidofovir in kidney transplant recipients with BK virus infection |